The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III, randomized, placebo-controlled study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy.
Thomas E. Hutson
No relevant relationships to disclose
Sergio Bracarda
No relevant relationships to disclose
Bernard Escudier
No relevant relationships to disclose
Camillo Porta
No relevant relationships to disclose
Robert A. Figlin
No relevant relationships to disclose
Emiliano Calvo
No relevant relationships to disclose
Viktor Grunwald
No relevant relationships to disclose
Alain Ravaud
No relevant relationships to disclose
Euloge Kpamegan
No relevant relationships to disclose
Robert John Motzer
No relevant relationships to disclose